Could a TB vaccine shield healthcare workers from COVID-19?
NCT ID NCT04387409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a vaccine called VPM1002 could help healthcare workers miss fewer days of work due to respiratory illnesses, including COVID-19. About 1,200 doctors, nurses, and other hospital staff received either the vaccine or a placebo. The goal was to see if the vaccine could boost the immune system and provide some protection against the coronavirus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
59 people
The number who actually took part.
- Started
-
May 2020
- Finished
-
Apr 2021
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult (≥18 years) * Male or female * Hospital personnel with expected high SARS-CoV-2 exposure * Subject is contractually capable, able to understand information on study and has signed informed consent sheet * Subject has access to an internet-enabled electronic device * Women of childbearing potential who are currently using reliable methods of birth control, have a negative pregnancy test during screening and have no intention to become pregnant for at least 3 months post-vaccination. Exclusion Criteria: * Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior BCG administration * Known active or latent Mycobacterium tuberculosis infection or with another mycobacterial species. A history with or suspicion of M. tuberculosis infection. * Fever (\>38 °C) within the past 24 hours * Pregnant or breast-feeding * Suspicion of active viral or bacterial infection * Participation of subject in another study within 30 days before screening and during this study * Person is an employee of the sponsor, a relative of the investigator or in direct reporting line to clinical trial staff at the clinical trial site * Severely immunocompromised subjects, such as: 1. subjects with known infection with the human immunodeficiency virus (HIV); 2. subjects with solid organ transplantation; 3. subjects with bone marrow transplantation; 4. subjects under chemotherapy, immunotherapy and radiotherapy; 5. subjects with primary immunodeficiency; 6. treatment with any anti-cytokine therapies; 7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months * Active solid or non-solid malignancy or lymphoma in the past 5 years * Direct involvement in the design or the execution of the present clinical trial * Expected absence from work of ≥4 of the following 12 weeks due to any reason (holidays, maternity leave, retirement, planned surgery etc) * Employed to the hospital \< 22 hours per week * Previous positive SARS-CoV-2 test result
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Infection, respiratory tract are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ludwig-Maximilians-Universität München
München, Bavaria, 80336, Germany
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
-
SocraTec R&D GmbH
Erfurt, Thuringia, 99084, Germany